Aquestive Therapeutics, Inc. AQST R2K
Company Overview
Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. It offers Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; EMYLIF, an oral film formulation of riluzole; ONDIF, an oral soluble film formulation of ondansetron; SYMPAZAN, an oral soluble film formulation of clobazam used for the treatment of seizures associated with a rare, intractable form of epilepsy; KYNMOBI, a sublingual film formulation of apomorphine; and AZSTARYS, an fda-approved, once-daily product for the treatment of ADHD in patients age 6 years or older. The company's proprietary pipeline products include Anaphylm, an epinephrine sublingual film, which is in phase 3 clinical trial for the emergency treatment of allergic reactions, including anaphylaxis; and AQST-108, a topical gel that is in phase 2 clinical trial for the treatment of alopecia areata. In addition, it develops PharmFilm technology for patients suffering from certain central nervous system disorders; and Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.
Recent Developments
- Dec 2025 Revenue of $44.55M (-22.6% YoY); net profit $-83.78M.
- Trailing 12 Months Year-on-year growth — revenue +65.7%.
- 5-Year Trend Long-term compounding — revenue CAGR -2.2%, profit CAGR -18.0%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -2.24% |
| 1 Year: | 65.70% |
Compounded Profit Growth
| 5 Years: | -18.00% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | +0.25% |
| 6 Months: | +3.32% |
| 3 Months: | -3.58% |
| 1 Month: | -4.04% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)41.69 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Revenue declined at -2.2% CAGR over 5 years.
- Earnings shrank at -18.0% CAGR over 5 years.
- Trading 46.1% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | AQST Aquestive Therapeutics, Inc. R2K | 4.04 | -6.62 | $506.82M | 0.00% | -59.11% | - | -2.24% | -18.00% |
| 2 | LLY Eli Lilly and Company SPX | 1,152.54 | 41.02 | $1.03T | 0.61% | - | 107.46% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPX | 253.85 | 29.45 | $611.07B | 2.23% | 14.88% | 26.42% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPX | 244.78 | 119.40 | $432.48B | 3.04% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPX | 425.19 | 32.02 | $386.13B | 2.27% | 9.74% | 12.18% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPX | 120.78 | 34.02 | $298.31B | 2.86% | - | 18.94% | 5.64% | 10.01% |
| 7 | AZN AstraZeneca PLC NDX | 164.50 | 24.81 | $255.12B | 1.77% | 15.97% | 23.48% | 9.82% | 45.96% |
| 8 | TMO Thermo Fisher Scientific Inc. SPX | 534.07 | 29.33 | $198.47B | 0.40% | 8.14% | 13.52% | 8.81% | 12.95% |
| 9 | AMGN Amgen Inc. NDXSPX | 355.25 | 24.69 | $191.73B | 2.84% | 18.02% | 101.32% | 11.77% | 5.58% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | 23.41M | 13.93M | 13.27M | 16.82M | 12.64M | 11.13M | 12.42M | 16.42M | 8.77M | 21.68M | 8.26M | 7.15M | 11.12M | 15.35M | 13.29M | 12.27M | 13.27M | 11.46M | 11.13M | 13.24M | 13.00M | 12.05M | 20.10M | - | - | 8.72M | 10.00M | 12.81M | 13.02M | 14.45M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 3.65M | 4.56M | 4.51M | 5.84M | 3.47M |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 5.07M | 5.44M | 8.30M | 7.18M | 10.98M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 24.43M | 16.81M | 19.78M | 36.02M | 15.18M |
| Operating Income | - | -4.06M | 10.42M | - | 5.30M | -32.71M | -9.21M | - | -13.07M | -18.69M | -11.00M | - | -13.86M | 395.00K | -13.78M | - | -8.53M | -6.52M | -7.97M | -9.74M | -12.76M | -8.85M | -4.61M | -4.21M | -2.38M | -8.96M | 55.00K | - | - | -19.36M | -11.37M | -11.48M | -28.84M | -4.20M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -18.51M | -9.13M | -11.03M | -27.46M | -4.01M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 4.28M | 4.28M | 4.27M | 4.27M | 3.94M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -22.93M | -13.55M | -15.45M | -31.86M | -8.06M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | -14.00K | - | - | - | - | - |
| Net Income | -1.46M | -5.90M | 8.45M | -10.04M | 4.10M | -36.49M | -15.04M | -13.94M | -14.73M | -20.47M | -18.41M | -12.64M | -16.53M | -2.33M | -16.55M | -20.37M | -14.67M | -12.37M | -14.55M | -13.22M | -16.30M | -12.54M | 8.07M | -5.79M | -2.04M | -12.83M | -2.75M | - | - | -22.93M | -13.55M | -15.45M | -31.86M | -8.06M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | -0.49 | -0.07 | -0.49 | - | -0.41 | -0.33 | -0.37 | -0.32 | -0.36 | -0.23 | 0.11 | -0.10 | -0.03 | -0.17 | -0.03 | - | - | -0.24 | -0.14 | -0.14 | -0.26 | -0.07 |
| R&D Expense | - | 4.84M | 5.68M | - | 4.90M | 7.99M | 4.53M | - | 4.30M | 8.15M | 5.06M | - | 4.35M | 3.85M | 7.26M | - | 3.66M | 4.26M | 4.73M | 4.77M | 5.20M | 3.23M | 3.55M | 3.47M | 3.20M | 5.93M | 4.16M | 5.27M | - | 5.36M | 4.11M | 4.53M | - | 4.20M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 66.92M | 67.43M | 52.61M | 45.85M | - | 47.68M | 50.58M | 57.56M | 44.55M |
| Cost of Revenue | - | - | - | - | - | 19.39M | 20.83M | 17.87M | 18.55M |
| Gross Profit | - | - | - | - | - | 28.29M | 29.75M | 39.69M | 25.99M |
| Operating Expenses | - | - | - | - | - | 70.36M | 44.85M | 70.46M | 97.04M |
| Operating Income | -113.00K | -48.93M | -52.67M | -42.89M | - | -42.07M | -15.10M | -30.77M | -71.05M |
| EBITDA | - | - | - | - | - | -39.58M | 1.18M | -26.62M | -66.14M |
| Interest Expense | - | - | - | - | - | 12.44M | 7.46M | 16.82M | 17.10M |
| Pretax Income | - | - | - | - | - | -54.41M | -7.62M | -44.15M | -83.78M |
| Tax Provision | - | - | - | - | - | 0 | 245.00K | -14.00K | 0 |
| Net Income | -8.94M | -61.38M | -66.25M | -55.78M | - | -54.41M | -7.87M | -44.14M | -83.78M |
| Diluted EPS | - | - | - | -1.66 | - | -1.12 | -0.13 | -0.51 | -0.78 |
| R&D Expense | 22.13M | 23.11M | 20.57M | 19.89M | 17.05M | 17.48M | 13.10M | 20.28M | 17.19M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 43.12M | 86.85M | 78.48M | 62.88M | - | 57.07M | 57.42M | 101.42M | 160.43M |
| Current Assets | - | - | - | - | - | - | 39.89M | 40.97M | 88.22M | 149.27M |
| Cash & Equivalents | 9.21M | 17.38M | 60.60M | 49.33M | 31.81M | - | 27.27M | 23.87M | 71.55M | 121.17M |
| Inventory | - | - | - | - | - | - | 5.78M | 6.77M | 6.04M | 6.17M |
| Receivables | - | - | - | - | - | - | 3.27M | 5.57M | 4.92M | 8.01M |
| Total Liabilities | - | 69.61M | 76.77M | 84.60M | 111.38M | - | 175.62M | 163.91M | 161.58M | 194.09M |
| Current Liabilities | - | 15.35M | 32.95M | 18.55M | 21.10M | - | 39.53M | 18.31M | 18.86M | 47.61M |
| Long Term Debt | - | - | - | 70.00M | 51.50M | - | 33.45M | 27.51M | 32.50M | 27.52M |
| Total Debt | - | - | - | - | - | - | 57.49M | 33.32M | 38.00M | 42.48M |
| Total Equity | -57.20M | -26.50M | 10.08M | -6.12M | -48.50M | - | -118.55M | -106.49M | -60.16M | -33.66M |
| Shares Outstanding | - | - | - | - | - | - | 54.83M | 68.53M | 91.41M | 122.04M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 5.82M | -12.99M | -60.21M | -45.46M | - | -9.82M | -6.38M | -35.76M | -52.43M |
| Investing Cash Flow | -2.07M | -1.82M | -663.00K | -517.00K | - | -2.52M | -995.00K | -159.00K | -562.00K |
| Financing Cash Flow | 4.41M | 58.03M | 49.60M | 28.46M | - | 11.59M | 3.97M | 83.59M | 102.62M |
| Capital Expenditure | -2.07M | -1.82M | -663.00K | -517.00K | - | -2.52M | -995.00K | -159.00K | -562.00K |
| Free Cash Flow | 3.76M | -14.81M | -60.87M | -45.98M | - | -12.34M | -7.38M | -35.92M | -52.99M |
| Net Change in Cash | - | - | - | - | - | -751.00K | -3.40M | 47.67M | 49.62M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | 59.3% | 58.8% | 69.0% | 58.3% |
| Operating Margin % | -0.2% | -72.6% | -100.1% | -93.6% | - | -88.2% | -29.9% | -53.5% | -159.5% |
| Net Margin % | -13.4% | -91.0% | -125.9% | -121.7% | - | -114.1% | -15.6% | -76.7% | -188.1% |
| ROE % | 33.8% | -608.9% | 1,082.1% | 115.0% | - | 45.9% | 7.4% | 73.4% | 248.9% |
| ROCE % | -0.4% | -90.8% | -87.9% | -102.7% | - | -239.8% | -38.6% | -37.3% | -63.0% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Bratton Capital Management, LP | 7.82% | 9.81M | $41.45M |
| 2 | Blackrock Inc. | 5.98% | 7.51M | $31.73M |
| 3 | RTW Investments LP | 5.92% | 7.43M | $31.38M |
| 4 | Vanguard Capital Management LLC | 3.54% | 4.44M | $18.77M |
| 5 | Federated Hermes, Inc. | 2.34% | 2.94M | $12.42M |
| 6 | Balyasny Asset Management LP | 2.31% | 2.90M | $12.25M |
| 7 | State Street Corporation | 2.03% | 2.55M | $10.76M |
| 8 | Samsara BioCapital, LLC | 1.99% | 2.50M | $10.56M |
| 9 | Geode Capital Management, LLC | 1.92% | 2.41M | $10.17M |
| 10 | Bank of America Corporation | 1.92% | 2.41M | $10.16M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for AQST
Aquestive Therapeutics to Participate in Leerink Partners Therapeutics Forum: I&I and Metabolism
WARREN, N.J., July 07, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative sc…
Aquestive Therapeutics (AQST) Moves 6.6% Higher: Will This Strength Last?
Aquestive Therapeutics (AQST) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.…
Does US manufacturing give drugmakers a speed edge?
Aquestive’s fast response to an FDA rejection reveals why some drugmakers are betting on domestic operations despite pricing pressures and overseas supply dependencies.
The Aquestive Therapeutics, Inc. (NASDAQ:AQST) First-Quarter Results Are Out And Analysts Have Published New Forecasts
As you might know, Aquestive Therapeutics, Inc. ( NASDAQ:AQST ) just kicked off its latest quarterly results with some...
Aquestive Therapeutics Inc (AQST) Q1 2026 Earnings Call Highlights: Revenue Surge and Strategic ...
Aquestive Therapeutics Inc (AQST) reports a 66% revenue increase and outlines strategic milestones, despite challenges in product launch timelines.
Aquestive Therapeutics Q1 Earnings Call Highlights
Aquestive Therapeutics (NASDAQ:AQST) said it remains on track to resubmit its new drug application for Anaphylm, its epinephrine sublingual film for severe allergic reactions, in the third quarter of 2026, while reporting higher first-quart…
AQST — Frequently Asked Questions
What is the current share price of Aquestive Therapeutics, Inc. (AQST)?
As of 2026-07-14 21:23 PDT, Aquestive Therapeutics, Inc. (AQST) trades at $4.04 on NasdaqGM. Its 52-week range is $2.95 to $7.49.
What is the market capitalisation of AQST?
Aquestive Therapeutics, Inc. (AQST) has a market capitalisation of $506.82M on NasdaqGM.
What is the P/E ratio of AQST?
AQST trades at a trailing price-to-earnings (P/E) ratio of -6.62. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is -15.22.
Is AQST a good stock to buy?
This page provides a data-driven analysis of Aquestive Therapeutics, Inc. (AQST), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.